This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Bringing the very first prescription digital therapeutic (PDT) to market in 2017, Pear Therapeutics went above and beyond to follow suggested regulatory guidelines, obtained Food & Drug Administration (FDA) clearance, and provided solid clinical study evidence. Photo: Bulat Silvia, Getty Images
In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”.
Our analysis included prescription trends for antibiotics, steroids, vitamins and ophthalmic-intraocular pressure reducing agents (prostaglandin analogs and alpha-adrenergic agonists) from 2018 to 2021. 9; 9/2017; p447; DOI:10.1016/j.je.2017.02.001 Learn more about the Clarivate real world data offering here. .”
Pharma brands work diligently to win the trust of key stakeholders—namely patients, caregivers, and healthcareproviders (HCPs). Even straightforward interactions like the initial prescription can be cluttered with unnecessary overlap and misalignment. It can have a real impact on the external perception of the brand.
Though 80% of healthcareproviders (HCPs) identified as “rep-accessible” in 2008 (that is, willing to meet with over 70% of the sales reps who try to approach them), that number had decreased to 44% in 2017. Increasing Market Awareness Remains a Challenge. This medication is not for people with type 1 diabetes.
In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. It potentially helps individuals lend some kind of concrete evidence to discussions with their healthcareprovider. Proteus’s profile grew considerably; it was soon valued at $1.5
Over recent years, the pharmacy has evolved from merely the point of filling a prescription to a highly frequented healthcare destination. The pharmacy is no longer simply the last stop on a patient’s healthcare journey. Centers for Disease Control and Prevention, November 16, 2017.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content